[1] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
Nuclear Medicine Association of the Chinese Medical Association.  Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
[2] Albano D, Bertagna F, Bonacina M, et al.  Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines[J]. Eur J Endocrinol, 2018, 179(3): 143-151.   doi: 10.1530/EJE-18-0253
[3] Chopra S, Garg A, Ballal S, et al.  Lung metastases from differentiated thyroid carcinoma: prognostic factors related to remission and disease-free survival[J]. Clin Endocrinol (Oxf), 2015, 82(3): 445-452.   doi: 10.1111/cen.12558
[4] Lang BHH, Wong KP, Cheung CY, et al.  Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis[J]. Ann Surg Oncol, 2013, 20(4): 1329-1335.   doi: 10.1245/s10434-012-2711-x
[5] Long B, Yang MD, Yang ZW, et al.  Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography[J]. Oncol Lett, 2016, 11(2): 965-968.   doi: 10.3892/ol.2015.4034
[6] Wang RF, Zhang YQ, Tan J, et al.  Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study[J]. Medicine (Baltimore), 2017, 96(19): e6809-.   doi: 10.1097/MD.0000000000006809
[7] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[8] Yang K, Wang H, Liang ZY, et al.  BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma[J]. Clin Nucl Med, 2014, 39(8): 675-679.   doi: 10.1097/RLU.0000000000000498
[9] Therasse P, Arbuck SG, Eisenhauer EA, et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.   doi: 10.1093/jnci/92.3.205
[10]

Li CY, Wu Q, Sun SG. Radioactive iodine therapy in patients with thyroid carcinoma with distant metastases: a SEER-based study[J]. Cancer Control, 2020, 27(1): 1073274820914661. DOI: 10.1177/1073274820914661.
[11] Matsuzu K, Sugino K, Masudo K, et al.  Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors[J]. Endocr J, 2020, 67(8): 869-876.   doi: 10.1507/endocrj.EJ20-0081
[12] Kim M, Kim WG, Park S, et al.  Initial size of metastatic lesions is best prognostic factor in patients with metastatic differentiated thyroid carcinoma confined to the lung[J]. Thyroid, 2017, 27(1): 49-58.   doi: 10.1089/thy.2016.0347
[13] 陈立波, 丁勇, 关海霞, 等.  中国临床肿瘤学会(CSCO)持续/复发及转移性分化型甲状腺癌诊疗指南-2019[J]. 肿瘤预防与治疗, 2019, 32(12): 1051-1080.
Chen LB, Ding Y, Guan HX, et al.  Guidelines of Chinese Society of Clinical Oncology (CSCO): persistent/recurrent and metastatic differentiated thyroid cancer-2019[J]. J Canc Control Treat, 2019, 32(12): 1051-1080.
[14] Yang X, Liang J, Li TJ, et al.  Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer[J]. Chin Med J (Engl), 2015, 128(8): 1058-1064.   doi: 10.4103/0366-6999.155086
[15] 王宸, 赵腾, 李娇, 等.  分化型甲状腺癌肺转移131I治疗后早期Tg变化与远期临床转归的关系[J]. 中华核医学与分子影像杂志, 2017, 37(9): 555-558.   doi: 10.3760/cma.j.issn.2095-2848.2017.09.007
Wang C, Zhao T, Li J, et al.  Relationship between the initial change of Tg and outcome in differentiated thyroid carcinoma patients with pulmonary metastases after 131I treatment[J]. Chin J Nucl Med Mol Imaging, 2017, 37(9): 555-558.   doi: 10.3760/cma.j.issn.2095-2848.2017.09.007
[16] 赵腾, 梁军, 李田军, 等.  分化型甲状腺癌131I治疗前刺激性Tg动态变化与远处转移的关系[J]. 中国医学科学院学报, 2015, 37(3): 315-319.   doi: 10.3881/j.issn.1000-503X.2015.03.013
Zhao T, Liang J, Li TJ, et al.  Relationship between variation of pre-ablation stimulated thyroglobulin and distant metastasis in patients with differentiated thyroid cancer[J]. Acta Acad Med Sin, 2015, 37(3): 315-319.   doi: 10.3881/j.issn.1000-503X.2015.03.013
[17]

Wang C, Zhang X, Li H, et al. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis[J/OL]. PLoS One, 2017, 12(7): e0179664[2022-03-23]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179664. DOI: 10.1371/journal.pone.0179664.
[18] 慕转转, 刘杰蕊, 鲁涛, 等.  血清Tg用于远处转移性分化型甲状腺癌131I治疗的疗效评估[J]. 中华核医学与分子影像杂志, 2020, 40(6): 329-333.   doi: 10.3760/cma.j.cn321828-20200220-00055
Mu ZZ, Liu JR, Lu T, et al.  Serum thyroglobulin in evaluating the response to 131I treatment in patients with distant metastatic differentiated thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2020, 40(6): 329-333.   doi: 10.3760/cma.j.cn321828-20200220-00055
[19] Miyauchi A, Kudo T, Miya A, et al.  Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy[J]. Thyroid, 2011, 21(7): 707-716.   doi: 10.1089/thy.2010.0355
[20] Kim HJ, Lee JI, Kim NK, et al.  Prognostic implications of radioiodine avidity and serum thyroglobulin in differentiated thyroid carcinoma with distant metastasis[J]. World J Surg, 2013, 37(12): 2845-2852.   doi: 10.1007/s00268-013-2213-4